The adverse effects of methamphetamine (METH) are of international and national concern (SAMSHA, 2010;UNODC, 2010). It is now clear the METH has toxic effects on the human brain. Animal studies have provided valuable information on the neurotoxic mechanisms and consequences of METH but the precise means by which METH causes brain damage remain unclear It is commonly and logically assumed that its neurotoxic effects are derived from its direct action on the brain. However, largely ignored are the myriad peripheral effects that might contribute to METH neurotoxicity. A likely peripheral source of these effects is the liver. It is known that the liver is a direct target of METH and man other drugs of abuse but no consideration has been given to whether liver or other peripheral organ damage is related to METH neurotoxicity. However, a well known consequence of acute liver damage is the neuropsychiatric syndrome, hepatic encephalopathy (HE). The key mediator of HE is hyperammonemia. Ammonia (NH3) causes neuronal damage through mechanisms strikingly similar to excitotoxicity and oxidative stress that have been implicated in METH-induced neurotoxicity. Specifically, NH3 increases glutamate (GLU) release, activates NMDA receptors, and down- regulates the GLU transporter, while inhibiting glutamine synthetase (condensation of GLU) and increasing superoxide radical and nitric oxide formation. This proposal will examine a new concept related to the neurotoxicity of METH by identifying a peripherally derived, novel mediator of METH-induced neurotoxicity based on exciting preliminary evidence implicating peripheral NH3 in the neurotoxic effects of METH. The long term goal is to identify the determinants of METH neurotoxicity to assess the risk to human health of repeated METH exposures. The objective is to elucidate the mechanisms by which METH causes damage to dopamine (DA) terminals. The central hypothesis is that METH causes a hyperammonemic state that triggers interdependent and convergent alterations in GLU homeostasis, excitotoxicity, and oxidative stress to GLUergic and DAergic regulatory proteins. These changes in turn, promote a feed-forward process that culminates in the classical METH neurotoxicity.
Specific Aim 1 will identify NH3 as a mediator of METH-induced damage to DA terminals while Specific Aim 2 will elucidate the excitotoxic/glutamatergic mechanisms underlying the effects of NH3 in METH- induced damage to DA.
Specific Aim 3 will build upon the other aims and determine if NH3 contributes to oxidative stress to DA terminals through a dysregulation of GLU transmission. Overall, the findings should have a positive impact because the identification of peripheral NH3 as a small molecule mediator of METH can lead to feasible therapeutic strategies for the treatment of METH overdose and neurotoxicity while fundamentally advancing the field of drug-induced brain damage in general. The proposal highlights the broader significance of peripheral organ toxicity in mediating neurological consequences.

Public Health Relevance

Project Narrative: The proposal is relevant to public heath because methamphetamine is a drug that is abused world-wide and is associated with neurological markers of damage in the human brain. The proposed studies will identify ammonia derived from damage in the periphery as a novel mediator of methamphetamine neurotoxicity. This project is relevant to NIDA's mission because it proposes to delineate how ammonia and peripheral organ damage can be feasibly targeted for the treatment of neurotoxicity produced by methamphetamine overdose.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA007606-21
Application #
8389280
Study Section
Special Emphasis Panel (ZRG1-IFCN-H (02))
Program Officer
Frankenheim, Jerry
Project Start
1992-07-15
Project End
2017-04-30
Budget Start
2012-07-01
Budget End
2013-04-30
Support Year
21
Fiscal Year
2012
Total Cost
$333,281
Indirect Cost
$110,797
Name
University of Toledo
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
807418939
City
Toledo
State
OH
Country
United States
Zip Code
43614
Natarajan, Reka; Northrop, Nicole; Yamamoto, Bryan (2017) Fluorescein Isothiocyanate (FITC)-Dextran Extravasation as a Measure of Blood-Brain Barrier Permeability. Curr Protoc Neurosci 79:9.58.1-9.58.15
Natarajan, Reka; Forrester, Laura; Chiaia, Nicolas L et al. (2017) Chronic-Stress-Induced Behavioral Changes Associated with Subregion-Selective Serotonin Cell Death in the Dorsal Raphe. J Neurosci 37:6214-6223
Blaker, Amanda L; Yamamoto, Bryan K (2017) Methamphetamine-Induced Brain Injury and Alcohol Drinking. J Neuroimmune Pharmacol :
Northrop, Nicole A; Halpin, Laura E; Yamamoto, Bryan K (2016) Peripheral ammonia and blood brain barrier structure and function after methamphetamine. Neuropharmacology 107:18-26
Rappeneau, Virginie; Blaker, Amanda; Petro, Jeff R et al. (2016) Disruption of the Glutamate-Glutamine Cycle Involving Astrocytes in an Animal Model of Depression for Males and Females. Front Behav Neurosci 10:231
Huff, Courtney L; Morano, Rachel L; Herman, James P et al. (2016) MDMA decreases glutamic acid decarboxylase (GAD) 67-immunoreactive neurons in the hippocampus and increases seizure susceptibility: Role for glutamate. Neurotoxicology 57:282-290
Collins, Stuart A; Huff, Courtney; Chiaia, Nicolas et al. (2016) 3,4-methylenedioxymethamphetamine increases excitability in the dentate gyrus: role of 5HT2A receptor-induced PGE2 signaling. J Neurochem 136:1074-84
Collins, Stuart A; Gudelsky, Gary A; Yamamoto, Bryan K (2015) MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors. Eur J Pharmacol 761:95-100
Stansley, Branden J; Yamamoto, Bryan K (2015) Behavioral impairments and serotonin reductions in rats after chronic L-dopa. Psychopharmacology (Berl) 232:3203-13
Stansley, Branden J; Yamamoto, Bryan K (2015) L-Dopa and Brain Serotonin System Dysfunction. Toxics 3:75-88

Showing the most recent 10 out of 64 publications